Medicale Corp. (MCLE) intrinsic value & 10-year financials
Medicale Corp. (MCLE) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.00
- Market cap
- $2.4K
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 198.2%
- Free cash flow (FY2025)
- —
MCLE 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$41.2K | -$0.01 | — | — | 28.0% |
| FY2024 | — | -$58.2K | -$0.01 | — | — | 78.3% |
| FY2023 | — | -$37.1K | -$0.01 | — | — | 78.7% |
| FY2022 | $0 | -$46.4K | -$0.01 | — | — | 147.1% |
| FY2021 | $0 | -$32.2K | -$0.01 | — | — | 659.0% |
| FY2020 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Medicale Corp. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Medicale Corp. has earned high returns on invested capital, averaging 67.8% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Medicale Corp. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Medicale Corp. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.